2023.05.26
I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023
The Company reports encouraging clinical results of uliledlimab at the ASCO Annual Meeting.